QbD and PAT – 2008 is the year it goes mainstream
publication date: Apr 7, 2008
Since the FDA revolutionary white papers in 2004, the industry has talked non-stop about the potential of PAT (Process Analytical Technology) and more recently, QbD (Quality by Design). These topics have found regular spots in conferences, press and internal company discussions. It has been widely stated that the benefits are potentially huge and that this way of developing and manufacturing life science products offers the opportunity to ‘catch up’ with other industries such as food and electronics, which have their processes down to a ‘science’ rather than an ‘art’.
Sorry, this page is available to members only.
If you have not registered with us yet, why not
register today for FREE and receive exclusive online access. Interested in receiving European Pharmaceutical Review in print? Subscribe today and guarantee the next six issues delivered direct to your desk, plus gain exclusive access online.
Why should I register online with European Pharmaceutical Review?
